Corcept Therapeutics submits NDA for the use of Corlux in Cushing's Syndrome
Pharmaceutical company Corcept Therapeutics Inc. Friday said it has submitted a New Drug Application or NDA for the use of Corlux in Cushing's Syndrome to the US Food and Drug Administration or FDA.
Simply, Cushing needs to get a new lawyer.